BIIB - Prevail Therapeutics Proposes IPO Terms
Quick Take
Prevail Therapeutics (PRVL) has filed to raise gross proceeds of $125 million from a U.S. IPO, according to an S-1/A registration statement.
The firm is developing Adeno-Associated Virus-based [AAV-based] gene therapies for the treatment of serious neurodegenerative diseases.
PRVL’s status is still pre-Phase 1 trial, so the IPO is an ultra-high-risk investment that is more suited to institutional investors with long timeframes for holding shares.
Company & Technology
New York-based Prevail Therapeutics was founded in 2017 to developed AAV-based gene therapies for the treatment of Parkinson’s Disease [PD] with GBA1